Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Nanomaterials (Basel, Switzerland)|January 12, 2021
α<sub>v</sub>β<sub>3</sub>-Specific Gold Nanoparticles for Fluorescence Imaging of Tumor AngiogenesisMarc Pretze, Valeska von Kiedrowski, Roswitha Runge, et al.
Plos One|September 2, 2016
Direct and Auger Electron-Induced, Single- and Double-Strand Breaks on Plasmid DNA Caused by 99mTc-Labeled Pyrene Derivatives and the Effect of Bonding DistanceFalco Reissig, Constantin Mamat, Joerg Steinbach, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 9, 2025
[<sup>203/212</sup>Pb]Pb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy-first clinical experienceEnrico Michler, David Kästner, Marc Pretze, et al.
Pharmaceutics|April 27, 2024
Investigation of Photodynamic Therapy Promoted by Cherenkov Light Activated Photosensitizers-New Aspects and RevelationsLisa Hübinger, Kerstin Wetzig, Roswitha Runge, et al.
Toxics|June 25, 2025
Different <sup>212</sup>Pb Generators and Its Radiation Safety Concerning <sup>220</sup>Rn (Thoron) EmanationMarc Pretze, Holger Hartmann, Charlotte Duchemin, et al.
International Journal of Radiation Biology|March 7, 2014
Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitroIris Eke, Mirjam Ingargiola, Claudia Förster, et al.
Biotechnology Journal|January 14, 2026
Engineering of High-Yield Recombinant Adeno-Associated Virus Producer PlasmidsMarco T Radukic, Dinh To Le, Robert Freudenberg, et al.
Bioconjugate Chemistry|October 17, 2015
Nuclear Targeting with an Auger Electron Emitter Potentiates the Action of a Widely Used Antineoplastic DrugSebastian Imstepf, Vanessa Pierroz, Paula Raposinho, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 23, 2020
Radiotherapy enhances uptake and efficacy of <sup>90</sup>Y-cetuximab: A preclinical trialAntje Dietrich, Michael Andreeff, Lydia Koi, et al.
Nuklearmedizin. Nuclear Medicine|January 29, 2026
177Lu-based radioligand therapy: A retrospective multicenter analysis to calculate the effective half-life and follow-up dose for the publicChristian Schütze, Markus Borowski, Martin Freesmeyer, et al.
Pageof 5